PsyBio Therapeutics Corp (CVE:PSYB) CEO Evan Levine explains to Proactive how it plans to manufacture low cost, biosynthesized psilocybin. Levine says the group's pharmaceutical grade psilocybin is currently being produced for clinical trials and research activities and it has initiated a pilot scale-up of its proprietary biosynthetic formulation of psilocybin in collaboration with Albany Molecular Research Inc.
PsyBio Therapeutics CEO explains how it plans to manufacture low cost, biosynthesized psilocybin
